- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06217887
Efficacy Comparison of Polyethylene Glycol Loxenatide and Gliclazide on the Brain Function in T2DM Patients
January 11, 2024 updated by: Yan Bi, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Efficacy Comparison of Polyethylene Glycol Loxenatide and Gliclazide on the Brain Function in T2DM Patients: a Randomized, Parallel Controlled Clinical Trial
This is a prospective, randomized, open label, parallel,4-month study to explore and evaluate the therapeutic effects of polyethylene glycol loxenatide on the cognitive function, olfactory function, and odor-induced brain activation in T2DM patients with normal cognitive status or MCI.
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
This is a prospective, randomized, open label, parallel, 4-month study to explore and evaluate the therapeutic effects of polyethylene glycol loxenatide on the cognitive function, olfactory function, and odor-induced brain activation in T2DM patients with normal cognitive status or MCI inadequately controlled with metformin monotherapy.
The control group was treated with Gliclazide.
There are 1 principal investigator, 6 sub-investigators and 1 nurse in research centre.
The sub-investigators will screen in the outpatient and inpatient departments to enroll 58 patients (29 patients for each arm) totally with the inclusion and exclusion criteria in 9 months.
The patients will be randomized at a 1:1 ratio into loxenatide and Gliclazide treatment group with a computer-generated random order.
All patients will also continue on their existing dose and regimen of metformin throughout the study.
At the baseline, clinical information collection, 100g-steamed bread meal test, biochemical measurement, body composition analysis, cognitive assessment, olfactory test and functional magnetic resonance imaging(fMRI) scan will be conducted for all patients.
During the treatment period, visits at 4-week intervals will be performed to evaluate the safety of drugs and adjust the dose of metformin if hypoglycaemia occurs; meanwhile, fasting and 2-hour postprandial plasma glucose assayed by fingerstick, physical examination, and olfactory test will be conducted.
At the end of the study, all of the assessments will be performed again for all recruited subjects, including early withdrawal patients.
Study Type
Interventional
Enrollment (Estimated)
58
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yan Bi, MD, PhD
- Phone Number: 86-25-83-105302
- Email: biyan@nju.edu.cn
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210008
- Recruiting
- Division of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University
-
Contact:
- Yan Bi, MD, PhD
- Phone Number: 86-25-83-105302
- Email: biyan@nju.edu.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- patients with type 2 diabetes mellitus ;
- Aged:40 -75 years ;
- Cognitive function assessment suggests normal status or mild cognitive impairment;
- a stable dose of metformin monotherapy (≥1,500 mg daily) for at least 90 days,
- HbA1c 7 - 10%;
- ≥6 years of education;
- Right-handed.
Exclusion Criteria:
- patients unable to complete brain MRI scanning;
- nasal disease that affected olfactory function;
- hepatic dysfunction with liver transaminases > 2.5 times upper normal limits and renal impairment with an estimated glomerular filtration rate < 60ml/min/1.73m2 ;
- acute cardio/cerebrovascular disease, psychiatric disorders, pancreatitis, acute infection, malignant tumor,thyroid disease and homorne drug use;
- a history of related drug allergy;
- alcohol or drug misuse;
- pregnant, breast-feeding or intending to become pregnant.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Gliclazide Group
Gliclazide will be initiated and maintained at 30mg/ day every morning until the completion of the study.
Meanwhile, all patients will also continue on their existing dose and regimen of metformin throughout the study.
Visits at 4-week intervals will be performed to evaluate the safety of drugs.
Metformin dose can be reduced in response to hypoglycaemia, but Gliclazide could not be adjusted.
If the plasma glucose still not achieve the target at the maximum dose, the maximum dose will be maintained until the completion of the study.
|
Gliclazide will be initiated and maintained at 30mg/day every morning.
If necessary, the dose can be increased to 120mg once daily.
All patients will also continue on their existing dose and regimen of metformin throughout the study.
Other Names:
|
Experimental: loxenatide Group
loxenatide will be initiated and maintained at 0.2mg once weekly until the completion of the study.
Meanwhile, all patients will also continue on their existing dose and regimen of metformin throughout the study.
Visits at 4-week intervals will be performed to evaluate the safety of drugs.
Metformin dose can be reduced in response to hypoglycaemia, but loxenatide could not be adjusted.
If the plasma glucose still not achieve the target at the maximum dose, the maximum dose will be maintained until the completion of the study.
|
Loxenatide will be initiated and maintained at 0.2mg once weekly until the completion of the study.
All patients will also continue on their existing dose and regimen of metformin throughout the study.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of olfactory brain activation by fMRI
Time Frame: from baseline to 4-month follow-up
|
Whether the activation degree of olfactory task fMRI brain area in the two groups after intervention was different from that before treatment and the difference of changes between the two groups.
All patients underwent odor-induced task fMRI on a 3.0T MR scanner with 222 volumes for task fMRI and 230 volumes for resting-state fMRI.
The odor-induced task consisted of "fresh air" "rest" and "scent".
Odor-induced brain activation was assessed by a general linear model using Statistical Parametric Mapping 12 (SPM12) software.
Following extraction of the three separate conditions "fresh air," "scent," and "rest" from the whole sequence, contrasts were made for each participant between "fresh air > rest" and "scent > rest."
Odor-induced fMRI data were analyzed in the mask of the olfactory network, including the regions of bilateral parahippocampus, amygdala, piriform cortex, insula, orbitofrontal cortex, hippocampus, and entorhinal cortices.
|
from baseline to 4-month follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of cognitive function
Time Frame: from baseline to 4-month follow-up
|
Cognitive function were improved, which means MoCA scores were improved after treatment, the RBANS total score increased by 0.5 standard deviation compared with baseline after treatment.
|
from baseline to 4-month follow-up
|
Change of metabolism
Time Frame: from baseline to 4-month follow-up
|
The changes of glycosylated hemoglobin among the two groups before and after intervention.
The level of glycosylated hemoglobin <7% means better glucose metabolism.
|
from baseline to 4-month follow-up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Zhang Z, Zhang B, Wang X, Zhang X, Yang QX, Qing Z, Zhang W, Zhu D, Bi Y. Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies. Diabetes Care. 2019 Jul;42(7):1274-1283. doi: 10.2337/dc18-2584. Epub 2019 May 21.
- Cheng H, Zhang Z, Zhang B, Zhang W, Wang J, Ni W, Miao Y, Liu J, Bi Y. Enhancement of Impaired Olfactory Neural Activation and Cognitive Capacity by Liraglutide, but Not Dapagliflozin or Acarbose, in Patients With Type 2 Diabetes: A 16-Week Randomized Parallel Comparative Study. Diabetes Care. 2022 May 1;45(5):1201-1210. doi: 10.2337/dc21-2064.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 10, 2020
Primary Completion (Estimated)
February 1, 2024
Study Completion (Estimated)
June 1, 2024
Study Registration Dates
First Submitted
December 20, 2023
First Submitted That Met QC Criteria
January 11, 2024
First Posted (Estimated)
January 23, 2024
Study Record Updates
Last Update Posted (Estimated)
January 23, 2024
Last Update Submitted That Met QC Criteria
January 11, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- z-2017-26-1902
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Diabetes Foundation, IndiaNational Diabetes Obesity and Cholesterol FoundationRecruitingType 2 Diabetes Mellitus With ComplicationIndia
Clinical Trials on loxenatide Group
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.UnknownType 2 Diabetes MellitusChina
-
Jiangsu HengRui Medicine Co., Ltd.Beijing Tongren HospitalCompleted
-
Jiangsu HengRui Medicine Co., Ltd.People's Liberation Army General Hospital of Chengdu Military RegionCompletedType 2 DiabetesChina
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.UnknownType 2 Diabetes Mellitus
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.UnknownType 2 Diabetes MellitusChina
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.China-Japan Friendship HospitalCompletedType 2 DiabetesChina
-
First Affiliated Hospital Xi'an Jiaotong UniversityCompleted
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.CompletedType 2 Diabetes MellitusChina
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.Completed